⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3812244 | 0.98 | EGLN1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL11787762 | 0.98 | EGLN1 (0.41) | — | |
| SCHEMBL14177603 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL11789819 | 0.78 | — | — | |
| SCHEMBL11789491 | 0.78 | EGLN1 (0.42) | — | |
| SCHEMBL21461381 | 0.77 | — | — | |
| SCHEMBL3816610 | 0.76 | CA2 (0.40) | — | |
| SCHEMBL3194539 | 0.76 | ECE1 (0.43) | — | |
| SCHEMBL3812157 | 0.76 | TET2 (0.35) | — | |
| Hydrochloric Acid SCHEMBL11786754 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306637-A | High-purity creatine monohydrate and preparation method thereof | 江苏金维氨生物工程有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119082183-A | Method for rapidly synthesizing creatine in plants | 浙江大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-119039182-A | Preparation method for continuously producing high-purity creatine monohydrate | 河北博泽化工有限责任公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118955333-A | Creatine monohydrate production system and production method | 宁夏恒康科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-117625503-A | Method for producing creatine by fermenting sugar raw material by utilizing microorganism | 江南大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-115669818-B | Feed additive for improving meat content of procambarus clarkia and application method thereof | 中国水产科学研究院长江水产研究所 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023276861-A1 | COMPOSITION FOR ORAL INGESTION FOR IMPROVING SPERM FINDING | 国立大学法人広島大学 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022239460-A1 | METHOD FOR ANALYZING BIOMOLECULE IN HAIR | 国立大学法人大阪大学 | 2022-11-17 | — | — | WO | disclosed |
| US-20220211651-A1 | COMPOSITION CONTAINING CREATINE FATTY ESTER FOR USE IN MEDICINE | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2022-07-07 | — | — | US | disclosed |
| CN-114630587-A | Stabilized creatine beverage | 可口可乐公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6444695-B1 | ADMINISTERING CREATINE; PREOVERCOATING PROSTHETICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-03 | — | — | US | disclosed |
| US-20020111316-A1 | INHIBITION OF THROMBIN-INDUCED PLATELET AGGREGATION BY CREATINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-15 | — | — | US | disclosed |